[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630172":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":154,"collaborators":26,"id":156,"slug":157,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":158,"sex":164,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":26,"studyType":170,"phases":171,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},{"fullName":5,"class":6},"Axsome Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Solriamfetol 150mg","EXPERIMENTAL","* In the open-label period;\n* In the randomized double-blind period (if applicable)",[13],"Drug: Solriamfetol 150 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","• In the randomized double-blind period (if applicable)",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Solriamfetol 150 MG","Solriamfetol tablets, taken once daily",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo tablets, taken once daily",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Study Director","CONTACT","2123325061","sol-mdd-302@axsome.com",[37,51,59,67,76,84,93,101,110,118,127,136,145],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":26},"Clinical Research Site","RECRUITING","Chino","California","91710","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-117.68894,34.01223,{"lat":49,"lon":48},{"facility":38,"status":39,"city":52,"state":41,"zip":53,"country":43,"countryCode":44,"cosmosGeoPoint":54,"geoPoint":58,"contacts":26},"Redlands","92374",{"type":46,"coordinates":55},[56,57],-117.18254,34.05557,{"lat":57,"lon":56},{"facility":38,"status":39,"city":60,"state":41,"zip":61,"country":43,"countryCode":44,"cosmosGeoPoint":62,"geoPoint":66,"contacts":26},"Walnut Creek","94596",{"type":46,"coordinates":63},[64,65],-122.06496,37.90631,{"lat":65,"lon":64},{"facility":38,"status":39,"city":68,"state":69,"zip":70,"country":43,"countryCode":44,"cosmosGeoPoint":71,"geoPoint":75,"contacts":26},"Jacksonville","Florida","32256",{"type":46,"coordinates":72},[73,74],-81.65565,30.33218,{"lat":74,"lon":73},{"facility":38,"status":39,"city":77,"state":69,"zip":78,"country":43,"countryCode":44,"cosmosGeoPoint":79,"geoPoint":83,"contacts":26},"Miami","33176",{"type":46,"coordinates":80},[81,82],-80.19366,25.77427,{"lat":82,"lon":81},{"facility":38,"status":39,"city":85,"state":86,"zip":87,"country":43,"countryCode":44,"cosmosGeoPoint":88,"geoPoint":92,"contacts":26},"Cherry Hill","New Jersey","08002",{"type":46,"coordinates":89},[90,91],-75.03073,39.93484,{"lat":91,"lon":90},{"facility":38,"status":39,"city":94,"state":86,"zip":95,"country":43,"countryCode":44,"cosmosGeoPoint":96,"geoPoint":100,"contacts":26},"Toms River","08755",{"type":46,"coordinates":97},[98,99],-74.19792,39.95373,{"lat":99,"lon":98},{"facility":38,"status":39,"city":102,"state":103,"zip":104,"country":43,"countryCode":44,"cosmosGeoPoint":105,"geoPoint":109,"contacts":26},"Brooklyn","New York","11235",{"type":46,"coordinates":106},[107,108],-73.94958,40.6501,{"lat":108,"lon":107},{"facility":38,"status":39,"city":111,"state":103,"zip":112,"country":43,"countryCode":44,"cosmosGeoPoint":113,"geoPoint":117,"contacts":26},"The Bronx","10464",{"type":46,"coordinates":114},[115,116],-73.86641,40.84985,{"lat":116,"lon":115},{"facility":38,"status":39,"city":119,"state":120,"zip":121,"country":43,"countryCode":44,"cosmosGeoPoint":122,"geoPoint":126,"contacts":26},"Cincinnati","Ohio","45215",{"type":46,"coordinates":123},[124,125],-84.51439,39.12711,{"lat":125,"lon":124},{"facility":38,"status":39,"city":128,"state":129,"zip":130,"country":43,"countryCode":44,"cosmosGeoPoint":131,"geoPoint":135,"contacts":26},"Portland","Oregon","97210",{"type":46,"coordinates":132},[133,134],-122.67621,45.52345,{"lat":134,"lon":133},{"facility":38,"status":39,"city":137,"state":138,"zip":139,"country":43,"countryCode":44,"cosmosGeoPoint":140,"geoPoint":144,"contacts":26},"Memphis","Tennessee","38119",{"type":46,"coordinates":141},[142,143],-90.04898,35.14953,{"lat":143,"lon":142},{"facility":38,"status":39,"city":146,"state":147,"zip":148,"country":43,"countryCode":44,"cosmosGeoPoint":149,"geoPoint":153,"contacts":26},"Dallas","Texas","75243",{"type":46,"coordinates":150},[151,152],-96.80667,32.78306,{"lat":152,"lon":151},{"type":155,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100630172","phase-3-clinical-assessment-of-response-in-the-treatment-of-depression-with-daytime-sleepiness-using-solriamfetol-100630172",false,"NCT07484217","Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol","A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms","CLARITY","Inclusion Criteria:\n\n* Currently meets the DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT\n* Excessive daytime sleepiness symptoms\n* Able to comply with study procedures\n* Male or female, aged 18 to 65 years inclusive\n\nExclusion Criteria:\n\n* Any clinically significant medical (e.g., OSA, narcolepsy), behavioral, or psychiatric disorder, other than MDD with EDS symptoms\n* Unable to comply with study procedures\n* Medically inappropriate for study participation in the opinion of the investigator","ALL","18 Years","65 Years",{"count":168,"type":169},508,"ESTIMATED","INTERVENTIONAL",[172],"PHASE3","CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.",[175],"Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms",[177,178,179,180,181,182,183,184,185,186,187],"Solriamfetol","Sunosi","Major Depressive Disorder with excessive daytime sleepiness","Major Depressive Disorder","MDD","Axsome","Non-stimulant therapy","Dopamine norepinephrine reuptake inhibitor","Trace amine-associated receptor 1 (TAAR1) agonist","Excessive daytime sleepiness","EDS","2026-03-16",{"date":190,"type":191},"2026-03-20","ACTUAL",{"date":193,"type":191},"2026-02-23",{"date":195,"type":169},"2028-12",{"name":5,"class":6},13]